Akynzeo is available as a prescription medication in the United States [1].
How is Akynzeo prescribed for patients?
Akynzeo is approved for use in adults as part of a combination therapy to help prevent nausea and vomiting caused by chemotherapy [1]. It is administered intravenously, typically given once before each round of chemotherapy [1].
What are the active ingredients in Akynzeo?
Akynzeo contains two active ingredients: netupitant and palonosetron [1]. Netupitant is a neurokinin-1 (NK1) receptor antagonist, and palonosetron is a serotonin-3 (5-HT3) receptor antagonist [1]. These ingredients work together to block pathways in the body that can trigger nausea and vomiting during chemotherapy [1].
How effective is Akynzeo in preventing chemotherapy-induced nausea and vomiting?
Clinical trials have shown Akynzeo to be effective in preventing both acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy [1]. In studies, a significant majority of patients experienced no vomiting or use of rescue medication for up to 120 hours after chemotherapy [1].
What are the potential side effects of Akynzeo?
The most common side effects reported in clinical trials include headache, fatigue, and constipation [1]. Less common side effects may also occur [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
When does the patent for Akynzeo expire?
The patent protection for Akynzeo and its components is a key factor in its market exclusivity. Information on specific patent expiration dates is available through resources like DrugPatentWatch.com [2]. This information is crucial for understanding when generic or biosimilar versions might become available.
Who manufactures Akynzeo?
Akynzeo is manufactured by Eisai Inc. [1].
What are alternative treatments for chemotherapy-induced nausea and vomiting?
Besides Akynzeo, other antiemetic medications are available to manage chemotherapy-induced nausea and vomiting. These may include other NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, and other classes of drugs, often used in combination therapies [3]. The choice of treatment depends on the type of chemotherapy used and individual patient factors [3].
---
1. Eisai Inc. Akynzeo Prescribing Information. Accessed October 26, 2023.
2. DrugPatentWatch.com. Akynzeo. Accessed October 26, 2023. https://drugpatentwatch.com/
3. National Cancer Institute. Nausea and Vomiting. Accessed October 26, 2023.